Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462839 | 0.84 | NOTUM (0.56) | NOTUMKCNJ1CYP19A1KEAP1RAB9A | |
| SCHEMBL29814679 | 0.83 | NOTUM (0.56) | NOTUM | |
| SCHEMBL18865501 | 0.82 | KCNJ1 (0.62) | NOTUMKCNJ1CYP19A1KEAP1RAB9A | |
| SCHEMBL460993 | 0.82 | NOTUM (0.59) | NOTUMMAPK9MAPK10KCNJ1CYP19A1 | |
| SCHEMBL6326873 | 0.81 | NOTUM (0.50) | NOTUMMAPK9MAPK10KCNJ1CYP19A1 | |
| SCHEMBL27245446 | 0.81 | NOTUM (0.61) | NOTUMMAPK9MAPK10KEAP1 | |
| SCHEMBL30010532 | 0.81 | NOTUM (0.61) | NOTUMMAPK9MAPK10KEAP1 | |
| SCHEMBL10447781 | 0.80 | NOTUM (0.78) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL17844194 | 0.79 | NOTUM (0.51) | NOTUMMAPK9MAPK10CYP19A1RAB9A | |
| SCHEMBL9969614 | 0.78 | NOTUM (0.54) | NOTUMMAPK9MAPK10CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4221704-B1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A | IMAGO BIOSCIENCES INC (US) | 2025-09-24 | — | — | EP | claimed |
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | DOMAIN THERAPEUTICS SA (FR) | 2025-07-01 | — | — | US | claimed |
| EP-4221704-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A | Imago Biosciences Inc. (US) | 2023-08-09 | — | — | EP | claimed |
| CN-111194306-B | Methods and processes for preparing KDM1A inhibitors | 伊美格生物科学公司 | 2023-05-16 | — | — | CN | claimed |
| US-11390590-B2 | Methods and processes for the preparation of KDM1A inhibitors | IMAGO BIOSCIENCES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | claimed |
| WO-2022072811-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A | IMAGO BIOSCIENCES, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| CN-101356864-B | Copper-clad laminate for chip on flexible board | LG CHEMICAL LTD | 2010-06-16 | — | — | CN | claimed |
| CN-101356864-A | Copper-clad laminate for chip on flexible board | LG CHEMICAL LTD (KR) | 2009-01-28 | — | — | CN | claimed |
| US-20250295660-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2025-09-25 | — | — | US | disclosed |
| US-20250275969-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2025-09-04 | — | — | US | disclosed |
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | DOMAIN THERAPEUTICS SA (FR) | 2025-07-01 | — | — | US | disclosed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250073232-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR TREATING MYELOID CANCERS | ORYZON GENOMICS SA (ES) | 2025-03-06 | — | — | US | disclosed |
| EP-3131897-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160636-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| CN-100413906-C | Polyhydroxycarboxylic acid and its production process | KUREHA CHEMICAL IND CO LTD (JP) | 2008-08-27 | — | — | CN | disclosed |
| CN-1525986-A | Polyhydroxycarboxylic acid and its production process | ��Ԩ��ѧ��ҵ��ʽ���� | 2004-09-01 | — | — | CN | disclosed |
| EP-1404738-A1 | POLYHYDROXYCARBOXYLIC ACID AND ITS PRODUCTION PROCESS | Kureha Chemical Industry Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003006525-A1 | POLYHYDROXYCARBOXYLIC ACID AND ITS PRODUCTION PROCESS | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED (JP) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275969-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | KDM1B, KDM3B, KDM1A | NOTUM 1891/4885MAPK9 2687/4885MAPK10 1863/4885 |
| US-20250073232-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR TREATING MYELOID CANCERS | DOT1L, EZH2, KDM1B | NOTUM 4648/4885MAPK9 942/4885MAPK10 731/4885 |
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | NOTUM 4145/4885MAPK9 2506/4885MAPK10 3605/4885 |
| US-20250295660-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | KDM1B, KDM2A, KDM1A | NOTUM 2359/4885MAPK9 3839/4885MAPK10 3831/4885 |
| US-11390590-B2 | Methods and processes for the preparation of KDM1A inhibitors | KDM1A, KDM4A, KDM7A | NOTUM 2771/4885MAPK9 1851/4885MAPK10 1449/4885 |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | NOTUM 4145/4885MAPK9 2506/4885MAPK10 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.